CBD Oil for Neurodegenerative Disease

Neurodegenerative diseases are a major cause of progressive clinical disability causing impaired quality of life with consequences not only for the patient, but also their carer and the state. Global demographics dictate that age-related disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (motor neuron disease) will increase in incidence and prevalence and inevitably present a significant economic challenge to both established and emerging...
More Description

Neurodegenerative diseases are a major cause of progressive clinical disability causing impaired quality of life with consequences not only for the patient, but also their carer and the state. Global demographics dictate that age-related disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (motor neuron disease) will increase in incidence and prevalence and inevitably present a significant economic challenge to both established and emerging economies [1,2]. There are also many other disorders that fall under the umbrella of neurodegenerative diseases including Huntington's disease, spinocerebellar ataxias, the non-Alzheimer dementias and common problems such as peripheral neuropathy, macular degeneration, and others.The challenge of neurodegenerative diseases needs to be met at several levels. Better facilities must be developed for diagnosis and treatment, and importantly for management of their clinical consequences and of their palliative phase. Undoubtedly the greatest unmet need is the availability of therapeutic interventions that are effective in slowing or preventing progression of the neurodegeneration. Logically, we would hope that a better understanding of the etiology and pathogenesis of these different diseases will provide the platform for the development of drugs targeted to intervene at one or more sites in the pathogenesis cascade. Recent advances in this area provide reason for cautious optimism. Furthermore, the more we learn of the causes of neurodegenerative diseases, the more we begin to appreciate the overlap and commonalities between them in, for instance, pathology and pathogenesis.Thus, there is a need for a greater and more detailed knowledge of the genetic basis and molecular pathology of neurodegenerative diseases. However, this must be matched by better clinical evaluation and understanding of the prodrome and evolution of these diseases and how to detect meaningful change in clinical trials that can reflect successful modification of disease progression in a manner and timescale that is attractive to medical industry.